The activation of both canonical and non-canonical TGF-β pathways can be detrimental to skeletal muscle and many studies have shown that inhibition of TGF-β signaling will ameliorate several types of myopathies (Burks et al., 2011; Cohn et al., 2007; Serrano et al., 2011). This evidence concerns the gene TGFB1 and myopathy.